Details of the Drug

General Information of Drug (ID: DMF9G7L)

Drug Name
Dibucaine
Synonyms
Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Pruritus EC90 Investigative [2]
Therapeutic Class
Anesthetics
Affected Organisms
Humans and other mammals
ATC Code
C05AD04: Dibucaine
C05AD: Local anesthetics
C05A: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05: VASOPROTECTIVES
C: CARDIOVASCULAR SYSTEM
D04AB02: Dibucaine
D04AB: Anesthetics for topical use
D04A: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D: DERMATOLOGICALS
N01BB06: Dibucaine
N01BB: Amides
N01B: ANESTHETICS, LOCAL
N01: ANESTHETICS
N: NERVOUS SYSTEM
S01HA06: Dibucaine
S01HA: Local anesthetics
S01H: LOCAL ANESTHETICS
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
S02DA04: Dibucaine
S02DA: Analgesics and anesthetics
S02D: OTHER OTOLOGICALS
S02: OTOLOGICALS
S: SENSORY ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 343.5
Logarithm of the Partition Coefficient (xlogp) 4.4
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C20H29N3O2
IUPAC Name
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
Canonical SMILES
CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
InChI
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
InChIKey
PUFQVTATUTYEAL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3025
ChEBI ID
CHEMBL1086
CAS Number
85-79-0
UNII
L6JW2TJG99
DrugBank ID
DB00527
TTD ID
D0P5GE
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Blocker [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dibucaine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Dibucaine and Prilocaine. Pain [MG30-MG3Z] [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7159).
2 Dibucaine FDA Label
3 Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
4 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
5 Cerner Multum, Inc. "Australian Product Information.".